Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology

Suzana Gispert · Alexander Kurz · Nadine Brehm · Katrin Rau · Michael Walter · Olaf Riess · Georg Auburger

Accepted: 31 July 2014 / Published online: 12 August 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract As the second most frequent neurodegenerative disorder of the aging population, Parkinson’s disease (PD) is characterized by progressive deficits in spontaneous movement, atrophy of dopaminergic midbrain neurons and aggregation of the protein alpha-synuclein (SNCA). To elucidate molecular events before irreversible cell death, we studied synucleinopathy-induced expression changes in mouse brain and identified 49 midbrain/brainstem-specific transcriptional dysregulations. In particular, complexin-1 (Cplx1), Rabl2a and 14-3-3epsilon (Ywhae) downregulation, as well as upregulation of the midbrain-specific factor forkhead box P1 (Foxp1) and of Rabgef1, were interesting as early mRNA level effects of alpha-synuclein triggered pathology. The protein levels of complexin-1 were elevated in midbrain/brainstem tissue of mice with A53T-SNCA overexpression and of mice with SNCA-knockout. The response of CPLX1 and Foxp1 levels to SNCA deficiency supports the notion that these factors are regulated by altered physiological function of alpha-synuclein. Thus, their analysis might be useful in PD stages before the advent of Lewy pathology. Because both alpha-synuclein and complexin-1 modulate vesicle release, our findings support presynaptic dysfunction as an early event in PD pathology.

Keywords Parkinson’s disease · Alpha-synuclein · Midbrain/brainstem expression changes · Presynaptic vesicles · Complexin-1 · Foxp1

Introduction

Parkinson’s disease (PD) is the second most frequent age-associated brain degeneration disorder, affecting about 1% of the population over 65 years of age. The PD-specific progressive movement deficit is mostly due to the severe affliction and cell death of midbrain nigrostriatal dopaminergic neurons [1]. Surviving neurons in vulnerable regions exhibit aggregates predominantly consisting of the protein alpha-synuclein, which are visualized as Lewy neurites and Lewy bodies, both in sporadic late-onset and most familial early onset PD variants [2].

Autosomal dominant PD with early clinical manifestation was observed in rare families, leading to the identification of alpha-synuclein (SNCA) protein missense mutations such as A53T (termed the PARK1 variant) and of SNCA gene duplication/triplication events (PARK4 variant) as the strongest causes of this pathology [3, 4]. Further recruitment of Parkinson’s families enabled identification of a list of disease genes responsible for monogenic PD [5]. In addition, recent characterization of very large collectives of late-manifesting sporadic PD cases through genome-wide allele association studies (GWAS) identified two regions on chromosome 4 (SNCA and GAK/CPLX1 loci) that contain genetic variants predisposing to multifactorial PD [6]. Variations in the SNCA gene 3′-untranslated region (3′-UTR) and its promoter correlated strongly with PD risk [7].

Alpha-synuclein is physiologically concentrated in axon terminals. It is associated with the lipid membranes of synaptic vesicles and interacts with synaptobrevin, a component of the SNARE complex, mediating vesicle exocytosis and neurotransmitter release [8]. Its toxic gain-of-function leads over time to impaired synaptic vesicle release and synaptic failure [9, 10]. Current investigations aim to elucidate alpha-synuclein-triggered pathology, concentrating on disease
stages before the occurrence of irreversible cell loss, when neuroprotective therapies might still be efficacious.

Here, we focused on two independent mouse lines of inbred FVB/N background with ~1.5-fold overexpression of human A53T-alpha-synuclein in nigrostriatal dopaminergic neurons under control of the heterologous neuron-specific prion-promoter. A53T-alpha-synuclein overexpression in these mice occurs in presynaptic nigral dopaminergic neurons and presynaptic cortical glutamatergic neurons, but not in postsynaptic striatal neurons. These mice display apparently normal movements at age 6 months, but progress to significantly impaired spontaneous locomotion by age 18 months, despite the absence of neuronal loss in the nigrostriatal projection [11]. Previous expression profiling in these mice identified a Homer-1a transcript dysregulation throughout the brain and a 14-3-3 epsilon protein upregulation selectively in the striatum as molecular effects of alpha-synuclein triggered pathology. The alterations in these signalling molecules were temporally correlated with reduced striatal dopamine release and deficient long-term depression [12–14, 9]. To gain insight into the mechanisms underlying the impairment in vesicle exocytosis and neurotransmitter release, we surveyed progressive expression changes in midbrain/brainstem tissue using genome-wide unbiased transcriptome profiling. Promising candidates were validated with quantitative immunoblots.

Results

Overexpression of A53T-Alpha-Synuclein Modulates Foxp1, Cplx1, Rab12a, Rabgef1 and Ywhae mRNA Levels in Mouse Midbrain/Brainstem

Previously documented (GEO database GSE20547, see also [12]) global transcriptome data from striatum, midbrain/brainstem and cerebellum of human A53T-alpha-synuclein overexpressing mice were filtered. We selected those significant changes at age 18 months relative to age 6 months, which were midbrain/brainstem-specific and were consistent between both transgenic mouse lines (PrPmtA and PrPmtB). Further selection prioritized those transcripts with no corresponding significant changes in wild-type midbrain/brainstem and in wild-type/transgenic striatum and cerebellum, resulting in the identification of 49 candidate effects of synucleinopathy (Table 1). Among the progressive upregulation effects, the increase of Foxp1 mRNA levels by A53T-alpha-synuclein overexpression was particularly interesting in view of our previous finding that Foxp1 (encoding forhead box P1) is downregulated in alpha-synuclein knockout mouse [15]. Thus, the midbrain-identity-mediating transcription factor Foxp1 appears to depend in its brain levels both on the gain-of-function and the loss-of-function of alpha-synuclein. Among the progressive downregulation effects, the decreased levels of Cplx1 (encoding complexin-1) selectively in the mutant midbrain/brainstem were especially interesting, in view of the co-localization of alpha-synuclein and complexin-1 at the SNARE complex. Other midbrain/brainstem-selective significant dysregulations of vesicle endocytosis/exocytosis pathway factors included the downregulation of Rab12a transcript and the upregulation of Rabgef1, in good agreement with previous observations that alpha-synuclein disrupts cellular Rab homeostasis [16]. More ubiquitous dysregulations were detectable for three 14-3-3 isoforms (Table 1 bottom), which are established downstream targets of alpha-synuclein function. 14-3-3 family isoforms heterodimerize to protect phosphoserine-phosphothreonine groups and are (1) sequence homologous to alpha-synuclein, (2) putative direct interactor proteins of alpha-synuclein, (3) expression-modulated by alpha-synuclein, (4) sequestered into the Lewy bodies, (5) able to change their levels in response to pathogenic alpha-synuclein mutations and thereby modulate neurotoxicity [17–20]. Thus, at least seven of the expression changes are credible in the light of their function and of previous knowledge about alpha-synuclein. All information per animal including age and sex with the resulting microarray data discussed in this publication is deposited in the NCBI’s database Gene Expression Omnibus (GEO) and is accessible through GEO series accession number GSE20547. Validation studies of Cplx1 mRNA expression in independent tissues by qPCR confirmed the significant downregulation in midbrain/brainstem of PrPmtA mice (Fig. 1).

Overexpression of A53T-Alpha-Synuclein Leads to Elevated Complexin-1 Protein Levels in Mouse Midbrain/Brainstem

We focused on the downregulation of midbrain/brainstem Cplx1 mRNA as a novel and promising effect, since the encoded protein complexin-1 is involved in the stimulus-dependent control of secretory vesicle exocytosis through the SNARE complex [21, 22]. Alpha-synuclein was also shown to modulate SNARE assembly and vesicle clustering, so this expression effect might constitute a very direct and early consequence of alpha-synuclein mutations. Densitometric analysis of immunoblots revealed a significant increase of complexin-1 protein levels in the midbrain/brainstem of aged A53T-alpha-synuclein overexpressing mice (Fig. 2a–c), despite Cplx1 mRNA downregulation. The alterations were readily apparent by ECL detection of membranes, making more sophisticated approaches such as near-infrared immunoblot detection or quantification by ELISA unnecessary.

Deficiency of Alpha-Synuclein Also Modulates the Complexin-1 Levels in Mouse Midbrain/Brainstem

These data obtained in A53T-alpha-synuclein overexpressing midbrain/brainstem complement previous observations from
The upper rows show all 49 genes with known functions, which exhibited significant and consistent progression changes in both transgenic midbrain/brainstem tissues, but not in wild-type midbrain/brainstem or striatum or cerebellum. Grey background with bold gene symbol were comments used to highlight the most promising novel expression effect of synucleopathy, Ctx1/β (encoding complex-I). The lower rows show known expression effects of synucleopathy for comparison, highlighting the best previously established transcript. (Column A) documents the Affymetrix probe set ID; (B, C) the relative expression (RE) values for transgenic lines PrPmtA and PrPmtB, respectively, highlighting changes >1.7 or <0.6 in bold letters; (D) the adjusted p value to judge significance after correction for multiple testing; (E–G) the lack of significant changes (0) in striatum (S) of wild type (WT) and the two transgenic lines (A and B), respectively; (H–J) the lack of significant changes in WT compared to significant upregulations (1) or downregulations (−1) in midbrain/brainstem (MB) tissue of two transgenic lines A and B, respectively; (K–M) the lack of significant changes in cerebellum (C) of wild type and two transgenic lines A and B, respectively; (N) the gene symbol to access GeneCards and NCBI online databases using different background colours to emphasize functional pathways in common between individual genes; (O) authors’ summaries on the functions of each gene product with respect to synaptic failure, according to GeneCards and PubMed online databases. The rows of the upper table part were ordered from top to descending significance.

### Table 1 Global transcriptome analysis of mice with nigrostriatal overexpression of human A53T-alpha-synuclein showing significant changes from age 6 to 18 months

| Affymetrix ID | Expression | RE PrPmtA | RE PrPmtB | adj. p value | WT.S. | A.S. | B.S. | WT.MB. | A.MB. | B.MB. | WT.C. | A.C. | B.C. | Gene Symbols | Comments by GeneCards and PubMed databases |
|---------------|------------|-----------|-----------|-------------|-------|-----|-----|--------|------|------|-------|-----|-----|----------------|---------------------------------------------|
| 1436222_at    | 5.989      | 0.525     | 0.000     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1436311_at    | 1.990      | 0.911     | 0.000     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1436340_at    | 0.275      | 0.012     | 0.000     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1436701_at    | 1.580      | 1.761     | 0.020     | 0.042       | 0     | 0   | 0   | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1435530_at    | 1.204      | 1.266     | 0.020     | 0.050       | 0     | 0   | 0   | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1434700_at    | 1.410      | 1.401     | 0.000     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1423146_at    | 1.948      | 1.118     | 0.046     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1421962_at    | 0.651      | 0.505     | 0.000     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1424901_at    | 0.653      | 0.572     | 0.000     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1427947_at    | 1.783      | 1.476     | 0.000     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1428203_at    | 1.533      | 1.421     | 0.000     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1417596_at    | 2.841      | 1.532     | 0.011     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |
| 1427947_at    | 0.734      | 0.728     | 0.013     | 0           | −1    | −1  | −1  | 0      | 0    | 0    | 0     | 0   | 0   | Ywhah          | Protein levels decreased in alpha+beta-synuclein KO mice (Chandra-S 2004 PNAS), downregulated Pdcd6ip / Alix |

### DNA damage factors

- DNA repair factors
- DNA replication factors
- DNA sequence replication factors

### Peroxisomal-lysosomal degradation factors

- Peroxidase factors
- Lysosomal enzyme induced by LPS

### Endocytosis/exocytosis/exosome vesicle pathway factors

- Endocytosis factors
- Exocytosis factors
- Exosome vesicle pathway factors

### Lamellipodia/filopodia-forming RAC1/CDC42 pathway factors

- Lamellipodia factors
- Filopodia factors

### Known as alpha-synuclein

- Alpha-synuclein
- Alpha-synuclein sequence homolog of alpha-synuclein (Ostrerova-N 1999 J Neurosci), interactor of alpha-synuclein (Xu-J 2006 PNAS), KO attenuates neuritogenesis (Lin-Y 2012 FASEB J)

---

**Note:** The table above provides a comprehensive overview of the gene expression changes in mice with nigrostriatal overexpression of human A53T-alpha-synuclein, highlighting the most significant changes across different pathways and tissues. The data are sourced from experiments conducted with Affymetrix microarrays and published in relevant scientific journals. The table includes gene symbols, relative expression values, adjusted p-values, and gene comments derived from GeneCards and PubMed, providing insights into the functions and impacts of these genes in the context of synucleopathy.
alpha-/beta-synuclein double-null mice, which exhibit upregulated complexin-1 and downregulated 14-3-3 epsilon protein in the whole brain [23]. To test whether alpha-synuclein or beta-synuclein is responsible for the observed changes, we studied midbrain/brainstem from mice with Snca knockout in 129/SvEv background [24] and demonstrated significant up-regulation for complexin-1 and downregulation for 14-3-3 epsilon protein (Fig. 2d–e). Thus, 14-3-3 isoform and complexin-1 protein levels respond not only to toxic gain-of-function mutations in alpha-synuclein but also to its loss-of-physiological function.

**Discussion**

Our data confirm previous findings that alpha-synuclein abundance modulates the levels of 14-3-3 isoforms. It was previously known that CPLX1 levels are altered in alpha + beta-synuclein double-knockout mice and that Foxp1 mRNA levels respond to the alpha-synuclein knockout. We now report novel findings that also pathogenic gain-of-function mutations of alpha-synuclein have a modulatory role on CPLX1 and Foxp1 in mice that showed no demonstrable alpha-synuclein aggregation in midbrain/brainstem during their lifespan and that CPLX1 levels change in the alpha-synuclein single knockout mouse brain.

This suggests that both CPLX1 and FOXP1 may be useful to monitor early stages of alpha-synuclein pathology. FOXP1 is expressed preferentially in the midbrain. In contrast, CPLX1 shows a more ubiquitous expression pattern, similar to alpha-synuclein. Although both CPLX1 and SNCA were mainly studied regarding presynaptic vesicle dynamics, their expression in brain is not much higher than in blood platelets, where they have a role in stimulus-dependent secretory vesicle exocytosis to control thrombus formation [25]. Thus, CPLX1 might have potential as biomarker to monitor an alpha-synuclein gain-of-function in peripheral tissues like blood.

Although our experiments were focused on modelling monogenic alpha-synucleinopathy variants of PD (PARK4/1), we are confident that complexin-1 plays a role in the genetically heterogeneous common idiopathic PD. Our data from alpha-synucleinopathy mouse models are consistent with a proteome survey of midbrain from sporadic PD patients, which reported significantly elevated levels for complexin-1 and a trend towards elevated levels of 14-3-3 epsilon [26]. Furthermore, the GAK/CPLX1 locus on chromosome 4 carries risk variants for sporadic PD in GWAS studies [6].

The accumulation of CPLX1 in spite of reduced Cplx1 mRNA levels is intriguing. A plausible explanation might predict that excess alpha-synuclein at the SNARE complex interacts with CPLX1 and impairs its degradation. This could occur as part of a sequestration process during the formation of alpha-synuclein oligomers and aggregates, reflecting incipient formation of inclusion bodies known as “Lewy neurites” or “Lewy bodies”. It has been observed that this aggregation process starts in the presynapses and sequesters local proteins such as synapsin [27]. Overall, the transcriptomic profiling of our PARK1/PARK4 mouse model identified plausible molecular correlates of early nigrostriatal dopaminergic neurotransmission deficits previously observed in this mouse [9].

In conclusion, the transcriptomic profiling of mouse midbrain/brainstem tissue with alpha-synuclein pathology has provided credible insights into early steps of pathogenesis, before the advent of neurodegeneration. Complexin-1 may be a better read-out of alpha-synucleinopathy than the previous gold standard 14-3-3.

**Materials and Methods**

**Ethics Statement** Mice were housed in accordance with the German Animal Welfare Act, the Council Directive of 24 November 1986 (86/609/EWG) with Annex II, the ETS123 (European Convention for the Protection of Vertebrate Animals) and the EU Directive 2010/63/EU for animal experiments at the FELASA-certified Central Animal Facility (ZFE) of the Frankfurt University Medical School.

**Mouse breeding and characterization** with brain dissection was carried out as described in the literature [28, 29, 24]. All studies of mouse mutants were in comparison with age- and sex-matched WT controls from the same inbred background line, which were bred and aged in parallel, under controlled light cycle, periodic health-monitoring, and individually ventilated cage housing. Dissection of brain regions occurred
Fig. 2 Quantitative immunoblots demonstrate dysregulated levels of complexin-1 and 14-3-3 epsilon proteins in the midbrain/brainstem of mice with alpha-synuclein mutation. Beta-actin was always used as loading control, and protein level ratios were normalized to WT. Representative membranes are shown at the left, bar graph statistics of quantification at the right. *p value <0.05, **p<0.01 and ***p<0.001. 

a Complexin-1 and complexin-2 were detected with the antibody from SySy, using midbrain/brainstem protein extracts from the transgenic line PrPmtA versus wild type (WT) (n=3 versus 4) at age 18 months, demonstrating significantly increased complexin-1 levels. 

b Midbrain/brainstem protein from transgenic line PrPmtB versus wild type (WT) (four vs. three) at age 18 months also showed significantly increased complexin-1 levels. 

c In comparison, selective detection of 14-3-3 epsilon abundance change (five vs. five) as a repeatedly published molecular effect of alpha-synucleinopathy failed to reveal changes in protein levels, in spite of its significantly changed mRNA levels in mouse midbrain/brainstem (Table 1). 

d Levels of complexin-1 and complexin-2 (antibody from SySy) were significantly increased in alpha-synuclein knockout mice (Snca KO) at age 3 months (five KO vs. four WT), in inverse correlation to alpha-synuclein levels, demonstrating that complexin levels respond not only to the toxic alpha-synuclein gain-of-function/aggregation process but also to its loss-of-function. 

e Significant downregulation of 14-3-3 epsilon (five KO vs. four WT). These data indicate that 14-3-3 epsilon protein levels are directly correlated to the loss-of-function of alpha-synuclein.
rapidly after cervical dislocation, placing the brain in a sagittal view to perform a coronal section from the hypophysis stem towards the caudal end of the hippocampus. Olfactory brain regions, the cerebral cortex, septal and thalamic tissue were removed from the ventral tissue block to isolate the striatum. To obtain midbrain/brainstem from the caudal tissue block, the cortical, dorsal thalamic and tectal tissues were removed, yielding the substantia nigra continuous with ventral tegmental area, red nucleus, mammillary nuclei and brainstem. For the dissection of the cerebellum, its peduncles were cut at the entry points into the hindbrain. All tissues were snap-frozen in liquid nitrogen and then stored at −80 °C. Extraction of protein and RNA was carried out as previously described [30]. The individual transcript expression validation on a StepOnePlus equipment (AppliedBiosystems) employed TaqMan assays (AppliedBiosystems) Mm00447333_m1 (Snca), Mm01198853_m1 (Cplx1) and Mm00446973_m1 (Tbp), with quantitative real-time reverse transcriptase polymerase chain reaction (qPCR) conditions as recommended for these assays.

**Genome-wide transcriptomics** of mouse brain regions was performed with Affymetrix oligonucleotide microarrays as previously reported [12].

**Quantitative Immunoblots** Frozen tissues were homogenized on ice in a glass-Teflon douncer in RIPA buffer with 50 mm Tris–HCl (pH 8), 150 mm NaCl, 1 % NP-40, 0.5 % Na-deoxycholate, 0.1 % SDS and protease inhibitor cocktail (Roche). Total lysates were briefly sonicated on ice, and cell debris was removed by centrifugation. Protein concentration was determined according to the method of Bradford. SDS–PAGE-separated proteins (20 μg/lane) were blotted onto a PVDF membrane (Bio-Rad) and probed. The following primary antibodies for mouse alpha-synuclein (1:1,000 BD Biosciences 610786), complex-1 (1:500 Acris AP51050PU-N and 1:1,000 Syn 122002), 14-3-3epsilon/eta/zeta/beta/gamma/theta (1:1,000 SantaCruz sc1020 and others from CellSignaling), beta-actin (1:1,000 Sigma A5441) were used with their corresponding secondary antibodies (GE Healthcare UK Limited LNA931V/AG for ECL-anti-mouse-HP from sheep and LNA934V/AG for ECL-anti-rabbit-HP from donkey) for 1 h. The detection was made with SuperSignal West Pico (Thermo Scientific), with varying exposure times to avoid film sensitivity or saturation problems as well as non-linear effects. The images were digitalized on a scanner (Epson) and densitometry performed with the proprietary ImageMaster Total Lab 2.00 software (AmershamPharmacia) or the public ImageJ software. After normalization of candidate protein values versus beta-actin values from the identical membrane in EXCEL, the changes were evaluated in GraphPad statistics and plotting.

**Statistical analyses** presented in bar graphs were performed by unpaired Student’s t tests and plotted with the Prism 3 software (GraphPad, La Jolla, CA, USA).

**Acknowledgments** We thank B. Meseck-Selchow for the technical assistance and the staff of the Zentrale Forschungs-Einrichtung at the University Hospital Frankfurt for their continued support. We are grateful to Herbert Zimmermann for the critical reading of the manuscript. The study was financed by funds of the University Hospital Frankfurt, the Bundesministerium für Bildung und Forschung (NGFNPplus Parkinson Net, Project 8.2.7), the Deutsche Forschungsgemeinschaft (GI 342/3-1), the European Union (ERAnet-RePARK network). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211
2. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9(1):13–24
3. Polymorphopolous MH, Lavedan C, Leroy E, Ide SE, Deheja A, Dutta A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazearin AM, Duivison RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045–2047
4. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hultihan M, Peuralinna T, Dutta A, Nussbaum R, Lincoln S, Crawford A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) alpha-Synuclein locus duplication causes Parkinson's disease. Science 302(5646):841
5. Corti O, Lesage S, Brice A (2011) What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 91(4):1161–1218
6. Lill CM, Koehr JT, McQueen MB, Kavouatra FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauf U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biemacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Bums EM, Klein C, Latourelle JC, Maraganore DM, Martin ER, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Singleton AB, Stefansson K, Toda T, Tung JY, Vance J, Wood NW, Zabetian CP, Young P, Tanzi RE, Khoury MJ, Zipp F, Lehrach H, Ioannidis JP, Bertram L (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet 8(3):e1002548
7. Rhinn H, Qiang L, Yamashita T, Rhee D, Zolin A, Vanti W, Abelovich A (2012) Alternative alpha-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. Nat Commun 3:1084
8. Diao J, Buré J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, Südhof TC, Brunger AT (2013) Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2:e00592
9. Pratt NJ, Gispert S, Auburger G, Cragg SJ (2012) Striatal dopamine transmission is subtly modified in human A53Talpha-synuclein over-expressing mice. PLoS ONE 7(5):e36397
10. Janevic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN, Potgieter D, Parkkinen L, Senior SL, Anwar S, Ryan B, Deltheil T, Kosillo P,
Cioroch M, Wagner K, Ansorge O, Bannerman DM, Bolam JP, Magill PJ, Cragg SJ, Wade-Martins R (2013) Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci U S A 110(42):E4016–E4025. doi: 10.1073/pnas.1309143110

11. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-20. Ding H, Fineberg NS, Gray M, Yacoubian TA (2013) alpha-20. Ding H, Fineberg NS, Gray M, Yacoubian TA (2013) alpha- synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24(2):419–429

12. Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, Garcia-Arencibia M, Nuber S, Schlaudraff F, Liss B, Fernandez-Ruiz J, Gerlach M, Wullner U, Luddens H, Calabresi P, Auburger G, Gispert S (2010) A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS ONE 5(7):e11464

13. Tozzi A, Costa C, Siliquini S, Tantucci M, Piccioni B, Kurz A, Gispert S, Auburger G, Calabresi P (2012) Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice. Neurobiol Aging 33(8):1792–1799

14. Kurz A, May C, Schmidt O, Muller T, Stephan C, Meyer HE, Gispert S, Auburger G, Marcus K (2012) A53T-alpha-synuclein overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. J Neural Transm 119(3):297–312

15. Kurz A, Wohr M, Walter M, Bonin M, Auburger G, Gispert S, Schwarting RK (2010) Alpha-synuclein deficiency affects brain FoxP1 expression and ultrasonic vocalization. Neuroscience 166(3): 785–795

16. Gitter AD, Bevis BJ, Shorter J, Strathern KE, Hamamichi S, Su LJ, Caldwell KA, Caldwell GA, Rochet JC, McCaffery JM, Barlowe C, Lindquist S (2008) The Parkinson’s disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A 105(1): 145–150. doi:10.1073/pnas.0710685105

17. Berg D, Riess O, Bormann A (2003) Specification of 14-3-3 proteins in Lewy bodies. Ann Neurol 54(1):135

18. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yaneker BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8(6): 600–606

19. Ostrenroda N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B (1999) alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19(4):5782–5791

20. Ding H, Fineberg NS, Gray M, Yacoubian TA (2013) alpha- Synuclein overexpression represses 14-3-3theta transcription. J Mol Neurosci 51(3):1000–1009. doi:10.1007/s12031-013-0086-5

21. Lin MY, Rohan JG, Cai H, Reim K, Ko CP, Chow RH (2013) Complexin facilitates exocytosis and synchronizes vesicle release in two secretory model systems. J Physiol 591(Pt 10):2463–2473

22. Reim K, Mansour M, Varoquaux F, McMahon HT, Sudhof TC, Brose N, Rosenmund C (2001) Complexins regulate a late step in Ca2+-dependent neurotransmitter release. Cell 104(1):71–81

23. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Sudhof TC (2004) Double- knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 101(41):14966–14971

24. Cabin DE, Gispert-Sanchez S, Murphy D, Auburger G, Myers RR, Nussbaum RL (2005) Exacerbated synucleinopathy in mice expressing A53T SNCA on a SncA null background. Neurobiol Aging 26(1): 25–35

25. Reheman A, Tasneem S, Ni H, Hayward CP (2010) Mice with deleted melanin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by melanin 1. Thromb Res 125(5):e177–e183

26. Basso M, Giraudo S, Corpolito D, Bergamasco B, Lopiano L, Fasano M (2004) Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics 4(12):3943–3952

27. Spinelli KJ, Taylor JK, Osterberg VR, Churchill MJ, Pollock E, Moore C, Meshul CK, Unni VK (2014) Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson’s disease. J Neurosci 34(6): 2037–2050. doi:10.1523/JNEUROSCI.2581-13.2014

28. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIwain KL, Orrison B, Chen A, Ellis CE,aylor R, Lu B, Nussbaum RL (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22(20):8797–8807

29. Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken HH, Becker D, Voos W, Leuner K, Muller WE, Kudin AP, Zimmermann A, Roper J, Wenzel D, Jendrach M, Garcia-Arencibia M, Fernandez-Ruiz J, Huber L, Rohrer H, Herrera M, Reichert AS, Rub U, Chen A, Nussbaum RL, Auburger G (2009) Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS ONE 4(6):e5777

30. Gispert S, Parganlija D, Klinkenberg M, Drose S, Wittig I, Mittelbronn M, Grzmił P, Kooob S, Hamann A, Walter M, Buchel F, Adler T, Hrabe de Angelis M, Busch DH, Zell A, Reichert AS, Brandt U, Osiewacz HD, Jendrach M, Auburger G (2013) Loss of mitochondrial peptidase ClpP leads to infertility, hearing loss plus growth retardation via accumulation of CLPX, mtDNA and inflammatory factors. Hum Mol Genet 22(24):4871–4887. doi:10.1093/hmg/ddt338